ORIC Pharmaceuticals (FRA:4TZ) Other Financing: €-0.30 Mil (TTM As of Mar. 2026)


FRA:4TZ ORIC Pharmaceuticals Inc FRA:4TZ
32 GF Score
Price €9.13
! 3 Warning Signs
View Full Analysis

What is ORIC Pharmaceuticals Other Financing?

ORIC Pharmaceuticals FRA:4TZ -2.77% 32 Other Financing is €-0.30 Mil as of Mar. 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ORIC Pharmaceuticals's Other Financing for the three months ended in Mar. 2026 was €0.22 Mil.

ORIC Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.30 Mil.

ORIC Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for ORIC Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ORIC Pharmaceuticals Other Financing Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -0.77 0.21 0.60 1.48 0.76

ORIC Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.33 -0.85 0.00 0.22
FRA:4TZ
32GF Score
ORIC Pharmaceuticals Inc FRA:4TZ
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ORIC Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-0.30 Mil mean?
ORIC Pharmaceuticals (FRA:4TZ) has a Other Financing of €-0.30 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for ORIC Pharmaceuticals and its competitors.
Is ORIC Pharmaceuticals' Other Financing too high?
ORIC Pharmaceuticals' current Other Financing is €-0.30 Mil. Overall, ORIC Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' Other Financing compare to DRTS and OLMA?
ORIC Pharmaceuticals' Other Financing of €-0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for ORIC Pharmaceuticals and its competitors. ORIC Pharmaceuticals's current Other Financing is €-0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current Other Financing of €-0.30 Mil. The current Other Financing is €-0.30 Mil. ORIC Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current Other Financing is €-0.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ORIC Pharmaceuticals Business Description

Other Exchanges ORIC:USA
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
32GF Score

Get the complete analysis for FRA:4TZ

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.13
Price